Argos Therapeutics (ARGS) Misses Q3 EPS by 10c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. CRWD
2. AAPL
3. LITE
4. PLTR
5. REGN
6. MRVL
7. ABBV
8. CL
9. CHKP
10. TFII

Go back to Argos Therapeutics (ARGS) Misses Q3 EPS by 10c

Argos Therapeutics (ARGS) Receives Funding from NIH DAIDS for AGS-004 Phase 2a

April 1, 2015 8:38 AM EDT

Argos Therapeutics (NASDAQ: ARGS) announced that the NIH Division of AIDS (DAIDS) has approved $6.6 million in funding for an investigator-initiated Phase 2a adult eradication study of AGS-004, the company's investigational fully personalized immunotherapy for HIV.

Eliminating the latent virus reservoir has been shown to be an essential goal in efforts to eradicate HIV. Research has shown that histone deacetylase (HDAC) inhibitors can... More